Trailing-twelve-month (TTM) revenue is $1.48 Billion with a year-over-year growth of +15.88%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $362,301,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q4 FY2025Period ended 2025-12-31 | $373,078,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-24 |
| Q1 FY2026Period ended 2026-03-31 | $363,611,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-05 |
| Q2 FY2026Period ended 2026-06-30 | $377,417,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-04 |
| TTM revenue | $1,476,407,000 |
Current P/S: $2,110,117,234 market capitalization ÷ $1,476,407,000 TTM revenue = 1.43x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T18:24:44.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $377.42M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T18:25:21.459Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Home Health | $16M | $25M | $34M | $57M | $70M | $71M |
| Hospice | $43M | $61M | $71M | $207M |
$1.48B
$1.48 Billion
+15.88%
vs. $1.27B a year ago (TTM)
+12.67%
5 Year compound annual growth rate
1 Year
+15.88%
3 Year
+13.90%
5 Year
+12.67%
10 Year
+15.08%
15 Year
+11.85%
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $1.42B | +$267.93M | +23.21% |
| 2024 | $1.15B | +$95.95M | +9.06% |
| 2023 | $1.06B | +$107.53M | +11.31% |
| 2022 | $951.12M | +$86.62M | +10.02% |
| 2021 | $864.50M | +$99.72M | +13.04% |
| 2020 |
TTM Growth
+15.88%
3-Year CAGR
+13.90%
5-Year CAGR
+12.67%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T18:25:21.459Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| $228M |
| $263M |
| Personal Care | $116M | $100M | $87M | $795M | $857M | $1.1B |
|---|
| $764.77M |
| +$115.98M |
| +17.88% |
| 2019 | $648.79M | +$130.67M | +25.22% |
| 2018 | $518.12M | +$92.40M | +21.71% |
| 2017 | $425.71M | +$25.03M | +6.25% |
| 2016 | $400.69M | +$63.87M | +18.96% |
